Mode
Text Size
Log in / Sign up
Phase 4 N=136 Prevention

Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women

HIV Prevention

Enrolled (actual)
136
Serious AEs
0.0%
Results posted
May 2020
Primary outcome: Primary: Adherence to PrEP — 22; 11; 30; 54 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Text Messaging (Behavioral); Adherence Counseling (Behavioral); Daily Oral PrEP (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of California, Los Angeles
Primary completion
May 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Adherence to PrEP
22; 11; 30; 54; 19; 21
SECONDARY
Number of Participants Experiencing Treatment-Emergent Adverse Events
72; 64
SECONDARY
Number of HIV Infections
SECONDARY
Correlates of PrEP Adherence
58; 50; 28; 55; 44; 37 <0.001 sig

Summary

The purpose of this study is to test a program that uses drug level monitoring, text messaging ("iTAB") and personalized counseling with HIV prevention services, including PrEP (medicine that can help prevent HIV infection when taken daily).

Eligibility Criteria

Inclusion Criteria

  • Female at birth and identifies as female gender
  • Age 18 years or older
  • Able to understand and provide consent in English or Spanish
  • HIV negative by 4th generation test (Ag/Ab test) or combination of enzymeimmunoassay (EIA) and HIV RNA
  • Creatinine clearance ≥ 60 ml/min (via Cockcroft-Gault formula)

At-Risk Criteria (at least one):

  • Condomless sex in the last 3 months with one or more male partners of unknown HIV status known to be at substantial risk of HIV infection (IDU, bisexual, sex for goods, recently incarcerated, from a country with HIV prevalence >1%, interpersonal Partner Violence);
  • STI (rectal or vaginal gonorrhea or syphilis) diagnosis during the last 6 months.
  • Previous post-exposure prophylaxis (PEP) use during the last 12 months.
  • Has at least one HIV-infected sexual partner for ≥4 weeks.
  • Sex for exchange of money, goods or services

Exclusion Criteria

  • Pregnancy at enrollment.
  • Any condition, which in the opinion of the provider, will seriously compromise the participant's ability to comply with the protocol, including adherence to PrEP medication dosing, such as active, untreated or unstable major mental illness (i.e. untreated psychotic disorder).
  • Use of prohibited medications, in particular, agents known to be nephrotoxic or drugs slow in renal excretion.
  • Previous participation in an HIV vaccine trial. Participants that were documented to have received only placebo are not excluded.
  • Signs or symptoms suspicious for Primary HIV Infection (PHI).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02584140). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search